SciClone Pharmaceuticals, Inc. Announces Accelerated Clinical Development Plans For SCV-07

SAN MATEO, CA -- (MARKET WIRE) -- February 05, 2007 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that based on an extensive review of positive human clinical trial and animal model results, it will initiate a controlled phase 2 dose-ranging clinical trial using its proprietary compound SCV-07 in the second quarter of 2007. In addition, the company is evaluating this compound in a variety of animal models of disease and will report the results of these studies in the third quarter.